Nanotechnology platform for cell-based magnetic assays

用于细胞磁性测定的纳米技术平台

• 批准号: 7086794
• 负责人: Mark S. DiIorio
• 金额: $ 12.01万
• 依托单位: MAGNESENSORS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7086794
• 关键词: biomagnetism measurement; biosensor device; cell surface receptors; cytology; immunologic assay /test; magnetic field; nanotechnology; particle; superconductivity; technology /technique development; temperature

DESCRIPTION (provided by applicant): MagneSensors' program is aimed at developing a nanotechnology platform that uses ultra-sensitive magnetic sensors and magnetic labels to perform powerful new cell assays on live cells. This magnetic detection platform uses high temperature (high-Tc) superconducting quantum interference devices (SQUIDs) to detect the magnetic field generated by biomolecules tagged with magnetic nanoparticles. The Phase I effort is specifically aimed at employing innovative nanotechnology to reduce and control critical dimensions in magnetic sensors and magnetic nanoparticle labels to drive next generation instrumentation and then demonstrating applicability in sensitive cell assays. Phase I uses model systems for proof-of-concept cell assays. Cell assay specific aims include: 1) detection of cell surface receptors (ICAM-1) on 100 adherent live cells (HUVEC), 2) detection of cell surface receptors (Ig) on 10 non-adherent live cells (CRL-1923), and 3) detection of 50 "rare" B cells in a background of 10,000 "normal" T cells. Smaller (10-20 nm) active devices to improve the magnetic sensors, and small (30-80 nm), more uniform, and more powerful magnetic nanoparticles are required to further push the instrument sensitivity towards the ambitious Phase II goals of single cell detection and rare cell detection. The benefits of the new cell assays include: a) the sensitive detection of rare cells within a "normal" cell population (such as fetal cells in maternal blood, metastatic tumor cells, infected host cells), b) ultra-sensitive "mix and measure" assays on cell surface receptors or proteins capable of being performed on a finger stick of blood and no sample preparation. The latter could eventually replace cell culturing for the rapid detection of infections (e.g. sepsis and septic shock) where an immediate answer is needed and delay can prove fatal. This "nanobiotechnology" program will benefit from the close interdisciplinary collaboration of an experienced group of physicists, chemists, and biologists.

描述（由申请人提供）： Magnesensors的程序旨在开发一个纳米技术平台，该平台使用超敏感的磁性传感器和磁标记在活细胞上执行强大的新细胞分析。该磁性检测平台使用高温（高-TC）超导量子干扰装置（鱿鱼）来检测由用磁性纳米粒子标记的生物分子产生的磁场。 第一阶段的努力专门用于采用创新的纳米技术来减少和控制磁性传感器和磁性纳米颗粒标签中的临界维度，以驱动下一代仪器，然后证明在敏感细胞测定中的适用性。第一阶段使用模型系统进行概念验证细胞测定。细胞测定特定目的包括：1）在100个粘附活细胞（HUVEC）上检测细胞表面受体（ICAM-1），2）在10个非辅助活细胞（CRL-1923）上检测细胞表面受体（Ig）（Ig）（Ig），而3）检测50”稀有的B细胞在10,000个“正常” T细胞的背景中。 需要较小的（10-20 nm）活动设备，以改善磁性传感器，并且需要小（30-80 nm），更均匀和更强大的磁性纳米颗粒，以进一步将仪器灵敏度推向单细胞检测和稀有细胞检测的雄心勃勃的II期目标。 新细胞分析的好处包括：a）在“正常”细胞群体中对稀有细胞的敏感检测（例如母体血液中的胎儿细胞，转移性肿瘤细胞，感染宿主细胞），b）在细胞表面受体或能够在血液上进行的蛋白质进行的细胞表面受体或蛋白质上的超敏感“混合和测量”测定。后者最终可以替代细胞培养，以快速检测感染（例如败血症和化粪池休克），其中需要立即答案，并且延迟可能致命。 这个“纳米元素技术”计划将受益于经验丰富的物理学家，化学家和生物学家的紧密跨学科合作。